New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
08:32 EDTANACAnacor announces publication of article describing boron-based compounds
Anacor Pharmaceuticals announced that a peer-reviewed article describing the recent progress of boron-based compounds in medicine and the properties of these compounds that support their development for the treatment of various skin disorders will be published in the February 17, 2014 edition of the Journal of Clinical and Aesthetic Dermatology. “From the Test Tube to the Treatment Room: Fundamentals of Boron-Containing Compounds and Their Relevance to Dermatology” is co-authored by James Q. Del Rosso, D.O., F.A.O.C.D., dermatologist in private practice at Las Vegas Skin and Cancer Clinics in Henderson, Nevada and Clinical Professor of Dermatology at Touro University College of Osteopathic Medicine in Henderson, Nevada and Jacob. J. Plattner, Ph.D., Senior Vice President of Research, Anacor Pharmaceuticals. The authors note that the therapeutic benefit of incorporating boron into a chemical compound is derived from boron’s unique physical, chemical and structural properties. The authors also note that, until recently, the use of boron in drug development has been widely overlooked. Boron-based compounds currently in development for dermatologic indications include tavaborole, which is being reviewed by the FDA for the treatment of toenail onychomycosis and AN2728, a PDE4 inhibitor which has completed Phase 2 studies in psoriasis and atopic dermatitis. A third compound, AN3365, is being evaluated as a gram-negative antibiotic. All three compounds were discovered and are being developed by Anacor Pharmaceuticals.
News For ANAC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
07:40 EDTANACAnacor price target raised to $80 from $70 at Jefferies
Jefferies analyst David Steinberg raised his price target for Anacor Pharmaceuticals to $80 from $70 saying Kerydin continues to exceed expectations. Sandoz has now fully completed its planned sales force expansion for the toenail fungus treatment, Steinberg tells investors in a research note, citing his industry contacts. Further, pivotal AN2728 Phase 3 data is expected in the coming weeks, the analyst points out. He ascribes 80% odds to a positive readout for the atopic dermatitis candidate, which he feels could push the shares past $100. Steinberg keeps a Buy rating on Anacor.
June 30, 2015
09:15 EDTANACAnacor price target raised to $85 from $72 at Wedbush
Wedbush believes that sales of Anacor's Kerydin drug have been impressive and could cause the company's Q2 results to beat expectations. The firm significantly raised its 2015-2017 Kerydin sales estimates and keeps an Outperform rating on Anacor.
June 29, 2015
08:35 EDTANACAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use